Welcome to our dedicated page for Azenta SEC filings (Ticker: AZTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. SEC filings for Azenta, Inc. (Nasdaq: AZTA), a life sciences company focused on cold-chain sample management and multiomics services. These regulatory documents offer detailed insight into how Azenta reports its financial performance, governance practices and executive compensation.
Core filings include the annual report on Form 10-K and quarterly updates on Form 10-Q, where Azenta discusses revenue from its Sample Management Solutions and Multiomics segments, separates products and services revenue, and explains trends in gross margin, operating expenses and adjusted EBITDA. Investors can review these filings to understand the contribution of sample storage, biorepository services and genomic analysis to the overall business.
Azenta’s current report filings on Form 8-K disclose material events such as quarterly and annual financial results, including segment performance and key metrics. For example, the company has furnished press releases detailing revenue growth, margin expansion and cash and liquidity positions, which are incorporated by reference into 8-K filings under Item 2.02.
The definitive proxy statement on Schedule 14A (DEF 14A) describes the structure of the Board of Directors, committee responsibilities, environmental, social and governance topics, and the executive compensation framework. It also outlines proposals submitted to shareholders, such as the election of directors, advisory votes on executive pay, amendments to the equity incentive plan and ratification of the independent auditor.
On Stock Titan, Azenta’s filings are updated as they appear on EDGAR, and AI-powered summaries can help explain lengthy documents like the 10-K, 10-Q, 8-K and DEF 14A. Users can quickly identify segment disclosures, non-GAAP reconciliations, compensation details and other key items without reading every page of the underlying filing.
Azenta, Inc. (AZTA) filed an amended Form 4 reporting an insider transaction by SVP and GM, Multiomics, Ginger Zhou. On 08/12/2025, a sale (transaction code S) of 1,085 shares of common stock was reported at a price of $28.54 per share.
Following the transaction, the reporting person beneficially owned 26,831 shares, held directly. The amendment also notes two administrative corrections: inclusion of a Power of Attorney that was omitted from the original filing on 08/13/2025, and correction of the transaction code from “D” to the correct code “S.”
Azenta insider sale tied to RSU vesting. Ginger Zhou, SVP and GM, Multiomics, disposed of 1,085 common shares on 08/12/2025 to satisfy withholding tax obligations arising from the vesting of 3,167 restricted stock units that vested on 08/09/2025. The reported sale price was $28.54 per share.
After the transaction the reporting person beneficially owned 26,831 shares. The Form 4 discloses this as a routine tax-withholding disposition rather than an open-market trading decision.
Azenta insider Olga Pirogova, who serves as SVP and CHRO, reported a disposition of common stock related to tax withholding on vested restricted stock units. The filing shows a sale of 1,085 shares at a reported price of $28.54 executed on 08/12/2025 to satisfy tax withholding obligations arising from the vesting on 08/09/2025 of 3,167 restricted stock units. After the transaction the reporting person beneficially owns 18,288 shares.
This is a routine, compensation-related sale rather than an unsolicited market disposition: the explanatory note explicitly states the sale was to meet withholding tax obligations on vested RSUs. No derivative transactions were reported in the filing.
Lawrence Y. Lin, Azenta's EVP, Chief Financial Officer and Treasurer, reported an open-market purchase of 2,500 common shares on 08/11/2025 at a price of $27.96 per share. After the transaction, his beneficial ownership increased to 46,013 shares.
The filing is a routine Form 4 disclosure showing an insider purchase executed in the open market. The report does not include any derivative transactions or indications of a planned trading program; the explanation provided states simply: "Open market purchase."
Azenta, Inc. filed a Current Report on Form 8-K dated August 5, 2025 announcing via press release its financial results for the fiscal quarter ended June 30, 2025.
The press release is attached as Exhibit 99.1 and the Cover Page Interactive Data File is included as Exhibit 104. The filing states the Item 2.02 disclosure and Exhibit 99.1 are not deemed "filed" under Section 18 of the Exchange Act and contains a cautionary note regarding forward-looking statements. The report was signed by Ephraim Starr, Senior Vice President, General Counsel and Secretary, dated August 5, 2025. This Form 8-K does not include any numerical financial metrics; readers should consult Exhibit 99.1 for the detailed results.